Beyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
About This Group of Stocks
Our Expert Thinking
AbbVie's successful transition from Humira to new blockbusters like Skyrizi and Rinvoq proves that pharmaceutical companies can thrive beyond patent cliffs. This creates opportunities in drugmakers with strong research pipelines that can replace aging products with innovative treatments, positioning them for long-term growth in the healthcare sector.
What You Need to Know
Patent cliffs occur when blockbuster drugs lose exclusivity, often causing significant revenue declines. However, companies with robust research and development capabilities can navigate this challenge by launching next-generation therapies. This group focuses on resilient pharmaceutical firms with proven or potential ability to manage these critical transitions.
Why These Stocks
These pharmaceutical companies were handpicked by professional analysts for their promising drug pipelines and demonstrated ability to replace revenues from expiring patents. Each firm represents the potential to unlock substantial growth as new revenue streams mature, making them attractive for long-term healthcare sector investment.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+26.22%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 26.22% over the next year.
Stocks Rated Buy by Analysts
13 of 17 assets in this group are rated Buy by professional analysts.
Group Growth
This group averaged a 1.1% return last month.
Why You'll Want to Watch These Stocks
Pipeline Power
These companies are proving that smart research and development can turn potential patent disasters into growth opportunities. When new drugs succeed, the rewards can be massive.
Innovation Advantage
AbbVie's success story shows that pharmaceutical companies with strong pipelines can not only survive patent cliffs but actually thrive. This blueprint could work for others in the group.
Expert-Backed Selection
Professional analysts handpicked these companies for their ability to navigate one of pharma's biggest challenges. Each represents potential for substantial long-term growth in healthcare.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AI's App Store Showdown
Elon Musk's threat of an antitrust lawsuit against Apple highlights the growing tension between AI developers and the powerful app store gatekeepers. This situation could create opportunities for other technology companies that offer alternative platforms or help developers navigate the competitive app landscape.
Navigating The Fed's Inflation Dilemma
A recent spike in inflation, driven by import tariffs, has put the Federal Reserve in a difficult position. This theme focuses on companies that could benefit from this economic tension, whether through competitive pricing or a potential interest rate cut.
Grounded Giant: Rivals Poised To Gain From Air Canada Strike
A potential strike at Air Canada threatens to ground the nation's largest airline, creating significant travel disruption. This presents a tactical opportunity for rival airlines to capture market share and benefit from the surge in demand from displaced travelers.
Frequently Asked Questions
Everything you need to know about the product and billing.